<DOC>
	<DOCNO>NCT02936375</DOCNO>
	<brief_summary>This study 52-week , randomize , open , active-controlled trial patient active diffused lupus nephritis , assess efficacy safety novel chemical synthetic agent iguratimod . The subject randomly receive iguratimod cyclophosphamide follow azathioprine , combine steroid .</brief_summary>
	<brief_title>Iguratimod Treatment Active Lupus Nephritis</brief_title>
	<detailed_description />
	<mesh_term>Nephritis</mesh_term>
	<mesh_term>Lupus Nephritis</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Azathioprine</mesh_term>
	<criteria>Active lupus nephritis : Fulfill ACR classification criterion ( 2009 ) SLE Proteinuria ≥1g/24h screen Nephritis class III , IV , V , III+IV IV+V , confirm renal pathology within 90 day prior screen Body weight ≥40kg SLE2K score ≥8 Agreement contraception Informed consent obtain Active severe SLEdriven renal disease unstable renal disease screen Active severe unstable neuropsychiatric SLE Clinically significant active infection include ongoing chronic infection History receive cyclophosphamide , azathioprine , tacrolimus , mycophenolate moetil rituximab treatment 90 day prior screen History human immunodeficiency virus ( HIV ) Confirmed Positive test hepatitis B positive test hepatitis C Active tuberculosis Live attenuate vaccine within 4 week prior screen Subjects significant hematologic abnormality Abnormal liver function test screening ( ALT , AST total bilirubin 2 fold upper normal level History peptic ulcer GI bleeding ; treatment warfarin anticoagulant within last 14 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>lupus</keyword>
	<keyword>nephritis</keyword>
	<keyword>iguratimod</keyword>
</DOC>